Filed with the United States Patent and Trademark Office (USPTO), the U.S. patent application number US 7,674,456 B2, Priority Date: June 14, 2004, includes the following:

  1. Compositions and cell lines
  2. Therapeutic methods of using compositions of SV-BR Cells

BriaCell has obtained the exclusive license to its patent application from St. Vincent’s Medical Center, and the resulting patent will have a term extending to 2024. Hatch-Waxman extension potentially applies (additional five years).

Additional patent applications with priority dates in 2016.